Will Monopar Therapeutics stock regain momentum as oversold conditions limit further selling?

Traders Union
All News
Stocks
Monopar Therapeutics drops 3.15% today

Highlights

Shares of MNPR trade below key short- and medium-term moving averages, showing ongoing seller pressure in the near term.
Technical indicators are mixed, with MACD suggesting a strong buy but multiple momentum tools signaling oversold and favoring sellers.
Forecast for the next 2 to 3 days expects MNPR price to fluctuate between $104.95 and $114.304, with a 75% chance of a downward move.

Bearish momentum dominates despite bullish divergence in indicators

On the hourly chart, MNPR is trading below its MA-20 at $112.38 and MA-50 at $112.98, highlighting technical selling pressure near-term. Price remains notably above the MA-200 at $74.09, and the Ichimoku Kijun at $112.80 stands as immediate resistance. Among key indicators, MACD shows Strong Buy, ADX is Neutral, while RSI (42.93) and CCI both signal Sell. Stoch RSI and Bull/Bear Power are in Oversold territory, reflecting dominant intraday selling. Awesome Oscillator is Neutral, and the technical picture is marked by a divergence: MACD’s bullish bias contrasts with bearish signals from RSI, CCI, Stoch RSI, and Bull/Bear Power.

Downward bias favors continued trading range unless resistance breaks

Over the next 2–3 sessions, MNPR is expected to fluctuate between $104.95 and $114.30, with a 75% probability for a downward move and only a 25% chance of an upward reversal. The baseline scenario calls for continued sideways trading near current levels. Should price break above $112.80 (Kijun resistance), a move higher could develop, while a close below $104.95 would point to further downside continuation.

Viktoras Karapetjanc, Traders Union expert, believes MNPR shows resilience above long-term levels but faces technical selling near-term. He sees mixed indicator signals, with the MACD staying bullish while several oscillators flag continued pressure. Price action lacks supportive news, so near-term volatility is likely. The baseline points to sideways movement, with $112.80 as resistance and $104.95 as key support. "If momentum manages a break above $112.80, I see good prospects for recovery, but the setup still favors range-bound action for now."

Earlier, analysts noted that Monopar Therapeutics was maintaining longer-term technical strength despite facing short-term selling pressure. The current technical setup reveals increased downside risk, with traders advised to monitor $104.95 as a critical support level for potential further weakness.

Source of Data: MNPR Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.